UPLIZNA® (inebilizumab-cdon) is engineered for efficient B-cell depletion

  • Inebilizumab-cdon is a CD19+ B cell-directed humanized immunoglobulin G1 (IgG1) monoclonal antibody¹
  • Following cell surface binding to CD19+ B lymphocytes, inebilizumab-cdon results in antibody-dependent cellular cytolysis (ADCC)1-4

CD19 is a cell surface antigen present on pre-B and mature B lymphocytes1,4

CD19 expression across lymphocyte maturation CD19 expression across lymphocyte maturation
  • The precise mechanism by which inebilizumab-cdon exerts a therapeutic effect in neuromyelitis optica spectrum disorder (NMOSD) is unknown¹

B-cell depletion through the randomized-controlled period of the pivotal trial

  • B-cell counts were reduced below the lower limit of normal by four weeks in 100% of patients treated with UPLIZNA and remained below the lower limit of normal in 94% of patients for 28 weeks after initiation of treatment1,5
Support programs

Access and Support

The Horizon By Your Side Team provides support your patients can count on.

Learn More
Patient resources

Resources for Your Patients

Conversation guides and downloadable materials to help inform and educate your patients about UPLIZNA.

See patient resources

References: 1. UPLIZNA (Inebilizumab-cdon) [prescribing information] Horizon 2. Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(1):131. 3. Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335:213-222. 4. Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11: 1756286418761697. doi: 10.1177/1756286418761697. 5. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352-1363. doi: 10.1016/S0140-6736(19)31817-3.